Generic Revlimid Flounders Amid Successful Q2 Performance At Sun

Firm’s US Unit Dropped 9% Sequentially Due To Lack Of Lenalidomide Contributions

 
• By Chloe Kent

Sun delivered an exceptional Q2 performance, marred by a 9% decline in its US business due to a significant drop in lenalidomide sales.

Orange -9% displayed against purple background
Declining sales of generic Revlimid caused a 9% drop to Sun's US business • Source: Shutterstock

More from Generics

More from Products